Another Promising Treatment for Alzheimer’s disease
Last week, Eli Lilly and Company announced that it has applied for U.S Food and Drug Administration (FDA) approval for its Alzheimer’s treatment, donanemab, and expects an FDA decision by the end of 2023. The data, released by Lilly, [View More]